Combination Therapy With DPP-4 Inhibitors and Insulin in Patients With Type 2 Diabetes Mellitus: What Is the Evidence?

References

• . Charbonnel B, Penfornis A, Varroud-Vial M, Kusnik-Joinville O, Detournay B. Insulin therapy for diabetes mellitus: treatment regimens and associated costs. Diabetes Metab. 2012;38(2):156–163
   PubMedGoogle Scholar
• . Li C, Ford ES, Zhao G, Tsai J, Balluz LS, Giles WH. Trends of insulin use among US adults with type 2 diabetes: the Behavioral Risk Factor Surveillance System, 1995–2007. J Diabetes Complications. 2012;26(1): 17–22
   PubMed Web of Science ®Google Scholar
• . Dailey G. Optimum management of type 2 diabetes—timely introduction, optimization and intensification of basal insulin. Diabetes Obes Metab. 2008;10( suppl 2):5–13
   PubMed Web of Science ®Google Scholar
• . Janka HU, Plewe G, Riddle MC, Kliebe-Frisch C, Schweitzer MA, Yki-Jarvinen H. Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes. Diabetes Care. 2005;28(2):254–259
   PubMed Web of Science ®Google Scholar
• . Fonseca V, Gill J, Zhou R, Leahy J. An analysis of early insulin glargine added to metformin with or without sulfonylurea: impact on glycaemic control and hypoglycaemia. Diabetes Obes Metab. 2011;13(9):814–822
   PubMedGoogle Scholar
• . Aschner P, Chan J, Owens DR, . EASIE Investigators. Insulin glargine versus sitagliptin in insulin-naive patients with type 2 diabetes mellitus uncontrolled on metformin (EASIE): a multicentre, randomised open-label trial. Lancet. 2012;379(9833):2262–2269
   PubMed Web of Science ®Google Scholar
• . ; ORIGIN Trial InvestigatorsGerstein HC, Bosch J, Dagenais GR, . Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med. 2012;367(4):319–328
   PubMed Web of Science ®Google Scholar
• . Inzucchi SE, Bergenstal RM, Buse JB, . American Diabetes Association (ADA); European Association for the Study of Diabetes (EASD). Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35(6):1364–1379
   PubMed Web of Science ®Google Scholar
• . Currie CJ, Peters JR, Tynan A, . Survival as a function of HbA(lc) in people with type 2 diabetes: a retrospective cohort study. Lancet. 2010;375(9713):481–189
   PubMed Web of Science ®Google Scholar
• . Peyrot M, Barnett AH, Meneghini LF, Schumm-Draeger PM. Insulin adherence behaviours and barriers in the multinational Global Attitudes of Patients and Physicians in Insulin Therapy study. Diabet Med. 2012;29(5):682–689
   PubMed Web of Science ®Google Scholar
• . Jabbour S. Primary care physicians and insulin initiation: multiple barriers, lack of knowledge or both? Int J Clin Pract. 2008;62:845–847
   PubMed Web of Science ®Google Scholar
• . Amiel SA, Dixon T, Mann R, Jameson K. Hypoglycaemia in type 2 diabetes. Diabet Med. 2008;25(3):245–254
   PubMed Web of Science ®Google Scholar
• . Verges B, Bran JM, Tawil C, Alexandre B, Kerlan V. Strategies for insulin initiation: insights from the French LIGHT observational study. Diabetes Metab Res Rev. 2012;28(1):97–105
   PubMedGoogle Scholar
• . Yki-Jarvinen H. Combination therapies with insulin in type 2 diabetes. Diabetes Care. 2001;24(4):758–767
   PubMedGoogle Scholar
• . Aviles-Santa L, Sinding J, Raskin P. Effects of metformin in patients with poorly controlled, insulin-treated type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1999;131(3):182–188
   PubMed Web of Science ®Google Scholar
• . Yki-Jarvinen H, Kauppinen-Makelin R, Tiikkainen M, . Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study. Diabetologia. 2006;49(3):442–151
   PubMed Web of Science ®Google Scholar
• . Kooy A, de Jager J, Lehert P, . Long-term effects of metformin on metabolism and microvascular and macrovascular disease in patients with type 2 diabetes mellitus. Arch Intern Med. 2009;169(6):616–625
   PubMedGoogle Scholar
• . Hemmingsen B, Christensen LL, Wetterslev J, . Comparison of metformin and insulin versus insulin alone for type 2 diabetes: systematic review of randomised clinical trials with meta-analyses and trial sequential analyses [published online ahead of print April 19, 2012]. BMJ.
   Google Scholar
• . Strowig SM, Raskin P. Combination therapy using metformin or thiazolidinediones and insulin in the treatment of diabetes mellitus. Diabetes Obes Metab. 2005;7(6):633–641
   PubMedGoogle Scholar
• . Raskin P, Rendell M, Riddle MC, Dole JF, Freed MI, Rosenstock J; Rosiglitazone Clinical Trials Study Group. A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes. Diabetes Care 2001;24(7):1226–1232
   PubMed Web of Science ®Google Scholar
• . Charbonnel B, DeFronzo R, Davidson J, . PROactive Investigators. Pioglitazone use in combination with insulin in the prospective pioglitazone clinical trial in macrovascular events study (PROactive 19). J Clin Endocrinol Metab. 2010;95(5):2163–2171
   PubMedGoogle Scholar
• . Riddle MC. Combined therapy with insulin plus oral agents: is there any advantage? An argument in favor. Diabetes Care. 2008;31( suppl 2):S125–S130
   Google Scholar
• . Yki-Jarvinen H. Combination therapy with insulin and oral agents: optimizing glycemic control in patients with type 2 diabetes mellitus. Diabetes Metab Res Rev. 2002;18( suppl 3):S77–S81
   PubMed Web of Science ®Google Scholar
• . Riddle MC, Rosenstock J, Gerich J; Insulin Glargine 4002 Study Investigators. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care. 2003;26(11):3080–3086
   PubMed Web of Science ®Google Scholar
• . Riddle MC. The Treat-to-Target Trial and related studies. Endocr Pract. 2006;12( suppl 1):71–79
   PubMedGoogle Scholar
• . Civera M, Merchante A, Salvador M, Sanz J, Martinez I. Safety and efficacy of repaglinide in combination with metformin and bedtime NPH insulin as an insulin treatment regimen in type 2 diabetes. Diabetes Res Clin Pract. 2008;79(1):42–47
   PubMedGoogle Scholar
• . de Luis DA, Aller R, Cuellar L, . Effect of repaglinide addition to NPH insulin monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care. 2001;24(10):1844–1845
   PubMedGoogle Scholar
• . Duran C, Tuncel E, Ersoy C, . The investigation of the efficacy of insulin glargine on glycemic control when combined with either repaglinide or acarbose in obese type 2 diabetic patients. J Endocrinol Invest. 2009;32(1):69–73
   PubMedGoogle Scholar
• . Wilding JP, Norwood P, T'joen C, Bastien A, List JF, Fiedorek FT. A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment. Diabetes Care. 2009;32(9):1656–1662
   PubMed Web of Science ®Google Scholar
• . Wilding JP, Woo V, Soler NG, ; Dapagliflozin 006 Study Group. Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial. Ann Intern Med. 2012;156(6):405–415
   PubMed Web of Science ®Google Scholar
• . Duttaroy A, Voelker F, Merriam K, . The DPP-4 inhibitor vildagliptin increases pancreatic beta cell mass in neonatal rats. Eur J Pharmacol 2011;650(2–3):703–707
   PubMedGoogle Scholar
• . Perfetti R, Hui H. The role of GLP-1 in the life and death of pancreatic beta cells. Horm Metab Res. 2004;36(11–12):804–810
   PubMedGoogle Scholar
• . Schweizer A, Dejager S, Foley JE. Impact of insulin resistance, body mass index, disease duration, and duration of metformin use on the efficacy of vildagliptin. Diabetes Ther. 2012;3(1):8
   PubMedGoogle Scholar
• . Dejager S, Schweizer A. Incretin therapies in the management of patients with type 2 diabetes mellitus and renal impairment. Hosp Pract (Min-neap). 2012;40(2):7–21
   PubMedGoogle Scholar
• . Kothny W, Shao Q, Groop PH, Lukashevich V. One-year safety, tolerability and efficacy of vildagliptin in patients with type 2 diabetes and moderate or severe renal insufficiency. Diabetes Obes Metab. 2012;14(11):1032–1039
   PubMed Web of Science ®Google Scholar
• . Aroda VR, Henry RR, Han J, . Efficacy of GLP-1 receptor agonists and DPP-4 inhibitors: meta-analysis and systematic review. Clin Ther. 2012;34(6):1247–1258
   PubMed Web of Science ®Google Scholar
• . Dejager S, Schweizer A. Minimizing the risk of hypoglycemia with vildagliptin: clinical experience, mechanistic basis, and importance in type 2 diabetes management. Diabetes Ther. 2011;2(2):51–66
   PubMedGoogle Scholar
• . Christensen M, Vedtofte L, Hoist JJ, Vilsboll T, Knop FK. Glucose-dependent insulinotropic polypeptide: a bifunctional glucose-dependent regulator of glucagon and insulin secretion in humans. Diabetes. 2011;60(12):3103–3109
   PubMed Web of Science ®Google Scholar
• . Foley JE, Jordan J. Weight neutrality with the DPP-4 inhibitor, vildagliptin: mechanistic basis and clinical experience. Vasc Health Risk Manag. 2010;6:541–548
   PubMedGoogle Scholar
• . Fonseca V, Schweizer A, Albrecht D, Baron MA, Chang I, Dejager S. Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes. Diabetologia. 2007;50(6):1148–1155
   PubMed Web of Science ®Google Scholar
• . Fonseca V, Baron M, Shao Q, Dejager S. Sustained efficacy and reduced hypoglycemia during one year of treatment with vildagliptin added to insulin in patients with type 2 diabetes mellitus. Horm Metab Res. 2008;40(6):427–430
   PubMedGoogle Scholar
• . Kothny W, Foley J, Kozlovski P, Shao Q, Gallwitz B, Lukashevich V. Improved glycaemic control with vildagliptin added to insulin, with or without metformin, in patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2013;15(3):252–257
   PubMedGoogle Scholar
• . Liqueros-Saylan M, Foley JE, Schweizer A, Couturier A, Kothny W. An assessment of adverse effects of vildagliptin versus comparators on the liver, the pancreas, the immune system, the skin and in patients with impaired renal function from a large pooled database of Phase II and III clinical trials. Diabetes Obes Metab. 2010;12(6):495–509
   PubMedGoogle Scholar
• . Schweizer A, Dejager S, Foley JE, Kothny W. Assessing the general safety and tolerability of vildagliptin: value of pooled analyses from a large safety database versus evaluation of individual studies. Vasc Health Risk Manag. 2011;7:49–57
   PubMedGoogle Scholar
• . Ved P, Shah S. Evaluation of vildagliptin and fixed dose combination of vildagliptin and metformin on glycemic control and insulin dose over 3 months in patients with type 2 diabetes mellitus. Indian J Endocrinol Metab. 2012;16( suppl 1):S110–S113
   Google Scholar
• . Vilsboll T, Rosenstock J, Yki-Jarvinen H, . Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes. Diabetes Obes Metab. 2010;12(2):167–177
   PubMed Web of Science ®Google Scholar
• . Arnolds S, Dellweg S, Clair J, . Further improvement in postprandial glucose control with addition of exenatide or sitagliptin to combination therapy with insulin glargine and metformin: a proof-of-concept study. Diabetes Care. 2010;33(7):1509–1515
   PubMed Web of Science ®Google Scholar
• . Hong ES, Khang AR, Yoon JW, . Comparison between sitagliptin as add-on therapy to insulin and insulin dose-increase therapy in uncontrolled Korean type 2 diabetes: CSI study. Diabetes Obes Metab. 2012;14(9):795–802
   PubMed Web of Science ®Google Scholar
• . Barnett AH, Charbonnel B, Donovan M, Fleming D. Effect of saxagliptin as add-on therapy in patients with poorly controlled type 2 diabetes on insulin alone or insulin combined with metformin. Curr Med Res Opin. 2012;28(4):513–523
   PubMed Web of Science ®Google Scholar
• . Charbonnel B, Barnett AH, Monyak J, Minervini G, Iqbal N. Efficacy and safety of saxagliptin in combination with insulin in elderly patients with type 2 diabetes [abstract]. Paper presented at: 72nd Scientific Session of the American Diabetes Association (ADA); June 8–12, 2012; Philadelphia, PA. Diabetes. 2012;61( suppl 1):1048-P
   Google Scholar
• . Rosenstock J, Rendell MS, Gross JL, . Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA(lC) without causing weight gain or increased hypoglycaemia. Diabetes Obes Metab. 2009;11(12):1145–1152
   PubMed Web of Science ®Google Scholar
• . Yki-Jarvinen H, Durán-Garcia S, Pinnetti S, . Efficacy and safety of linagliptin as add-on therapy to basal insulin in patients with type 2 diabetes [abstract A255]. Paper presented at: 72nd Scientific Session of the American Diabetes Association (ADA); June 8–12, 2012; Philadelphia, PA. Diabetes. 2012;61( suppl 1):999-P
   Google Scholar
• . Lukashevich V, Schweizer A, Shao Q, Groop PH, Kothny W. Safety and efficacy of vildagliptin versus placebo in patients with type 2 diabetes and moderate or severe renal impairment: a prospective 24-week randomized placebo-controlled trial. Diabetes Obes Metab. 2011;13(10):947–954
   PubMedGoogle Scholar
• . Lukashevich V, Schweizer A, Foley JE, Dickinson S, Groop PH, Kothny W. Efficacy of vildagliptin in combination with insulin in patients with type 2 diabetes and severe renal impairment. Vasc Health Risk Manag. 2013;9:21–28
   PubMedGoogle Scholar
• . Nowicki M, Rychlik I, Haller H, Warren ML, Suchower L, Gause-Nilsson I; D1680C00007 Investigators. Saxagliptin improves glycaemic control and is well tolerated in patients with type 2 diabetes mellitus and renal impairment. Diabetes Obes Metab. 2011;13(6):523–532
   PubMed Web of Science ®Google Scholar
• . Nowicki M, Rychlik I, Haller H, . Long-term treatment with the dipeptidyl peptidase-4 inhibitor saxagliptin in patients with type 2 diabetes mellitus and renal impairment: a randomised controlled 52-week efficacy and safety study. Int J Clin Pract. 2011;65(12):1230–1239
   PubMed Web of Science ®Google Scholar
• . McGill JB, Sloan L, Newman J, . Long-term efficacy and safety of linagliptin in patients with type 2 diabetes and severe renal impairment: a 1-year, randomized, double-blind, placebo-controlled study. Diabetes Care. 2013;36(2):237–244
   PubMed Web of Science ®Google Scholar
• . Arjona Ferreira JC, Marre M, Barzilai N, . Efficacy and Safety of Sitagliptin Versus Glipizide in Patients With Type 2 Diabetes and Moderate-to-Severe Chronic Renal Insufficiency. Diabetes Care. 2012
   Google Scholar
• . Chan JC, Scott R, Arjona Ferreira JC, . Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency. Diabetes Obes Metab. 2008;109(7):545–555
   Google Scholar
• . Ahren B, Schweizer A, Dejager S, . Vildagliptin enhances islet responsiveness to both hyper- and hypoglycemia in patients with type 2 diabetes. J Clin Endocrinol Metab. 2009;944(4):1236–1243
   Google Scholar
• . Farngren J, Persson M, Schweizer A, Foley JE, Ahren B. Vildagliptin reduces glucagon during hyperglycemia and sustains glucagon counter-regulation during hypoglycemia in type 1 diabetes. J Clin Endocrinol Metab. 2012;97(10):3799–3806
   PubMed Web of Science ®Google Scholar
• . Foley JE, Ligueros-Saylan M, He YL, . Effect of vildagliptin on glucagon concentration during meals in patients with type 1 diabetes. Horm Metab Res. 2008;40(10):727–730
   PubMed Web of Science ®Google Scholar
• . Ahren B, Schweizer A, Dejager S, Villhauer EB, Dunning BE, Foley JE. Mechanisms of action of the dipeptidyl peptidase-4 inhibitor vildagliptin in humans. Diabetes Obes Metab. 2011;13(9):775–783
   PubMed Web of Science ®Google Scholar